Ten post jest także dostępny w języku: polski
Bioceltix, a Wroclaw-based start-up, is starting a project to develop a biological drug for veterinary medicine. Based on stem cells, the product will be used to treat, among others, equine arthritis in horses.
NCBR grant will support veterinary medicine
The Bioceltix project was ranked 1st on the latest ranking list of the National Centre for Research and Development (NCBR). It includes projects that will be financed within the so-called fast track. This means that the company received a grant of PLN 5.1m for the implementation of a project worth over PLN 7m.
The Wroclaw-based start-up wants to enter the veterinary market, which is currently dominated by chemical drugs. The company’s representatives, quoted by wroclaw.pl, emphasize that the therapies currently available on the market cause only a temporary relief and are associated with the risk of serious side effects. Additionally, in the case of sports horses, anti-inflammatory drugs are treated as doping, which excludes animals from the competition.
Four biological drugs in development
Bioceltix is currently developing four biological drugs for use in animals. They are all based on allogeneic stem cells. In addition to the product described above for the treatment of osteoarthritis in horses, these are two drugs for use in dogs. They will be used in the case of osteoarthritis and the treatment of general autoimmune and inflammatory diseases. The fourth product on which Bioceltix conducts research is a cat medicine for the treatment of chronic oral cavity and gum inflammation.
As the representatives of the company emphasize in the conversation with wroclaw.pl, the market of veterinary biological drugs is currently in the initial phase of development. Only two years ago, the first such product was registered with the European Medicines Agency (EMA). It was Zoetis drug used in the treatment of atopic dermatitis. The EMA approval was also granted to a biological medicine used to treat lameness in horses. Bioceltix also plans to follow the full EMA registration path.